Key facts
- X9’s last known valuation is $21.5M (Nov 2025).
- It has raised $13.7M; the latest was Early Stage VC ($8.6M) in Nov 2025.
- Notable investors include ExploraMed, M&L Group.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for X9
- ·The full record, as it builds
Funding rounds
No funding rounds for X9 are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About X9
Developer of robotic medical imaging and procedural assistance technology intended for minimally invasive diagnostics and interventions. The company's platform integrates real-time AI-guided ultrasound imaging with robotic precision and a single-handed interface, enabling healthcare providers across hospital and outpatient settings to perform delicate procedures with increased accuracy, reduced variability, automated data capture while minimizing training requirements and administrative burden.
- Sector
- Healthcare
- HQ
- Wallingford, CT, United States
- Founded
- 2022
- Employees
- 7
- Ownership
- Privately Held (backing)
X9 doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in X9 shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on X9 in its N-PORT filings yet. We sweep new filings monthly.